Prognostic Impact of FLT3-ITD Microclones in AML: An EHA AML-Specialized Working Group Study
Identifying tiny FLT3-ITD mutations could help doctors better predict which AML patients need more aggressive treatment despite current risk classifications.
This EHA AML Working Group multicenter study evaluated FLT3-ITD microclones (allelic ratio <0.05) and found they independently predict inferior outcomes despite 2022 ELN intermediate-risk reclassification. Results directly challenge current AML risk stratification and have immediate implications for treatment selection, consolidation strategy, and transplant allocation.
What the study was
- Study design
- Retrospective multicenter cohort study
- Population
- AML patients with FLT3-ITD mutation across multiple European centers
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- American journal of hematology
Why it surfaced
Multicenter EHA Working Group study challenging ELN 2022 AML risk stratification; FLT3-ITD microclone detection has direct clinical utility for treatment planning in high-mortality disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.